The metastasis suppression role of CD82 is well-defined in hepatocarcinoma, melanoma, sarcoma, pancreatic and breast cancer cell lines [27]–[31], and it has been observed that down regulation of CD82 mRNA and protein is associated with advanced stages of many malignancies including prostate, colon, lung, pancreatic, breast, ovarian and other cancers, suggesting the loss of CD82 contribute to the increased invasiveness of these cancers. Here, CD82 is linked to melanoma.